Luma AI Raises $900 Million Series C Led by HUMAIN And Partners on 2 Gigawatt AI Supercluster in Saudi Arabia
19.11.2025 18:15:00 CET | Business Wire | Press release
New capital and compute infrastructure will accelerate Luma AI’s path towards Multimodal AGI – AI that can simulate reality and help humans in the physical world.HUMAIN to build Project Halo, one of the world’s largest AI compute clusters that will include the training of World Models, the next step in AI after LLMs - a potential trillion-dollar opportunity spanning entertainment, marketing/brands, education, world understanding, and robotics industries.Partnership includes HUMAIN Create, an initiative to build AI models trained on Arabic and regional data, helping enterprises and governments across MENA adopt culturally aligned AI.
Luma AI, the frontier artificial intelligence company building multimodal AGI, today announced it has raised $900 million in Series C funding, led by HUMAIN, a PIF company delivering global full-stack AI solutions, with significant participation from AMD Ventures, and existing investors Andreessen Horowitz, Amplify Partners, and Matrix Partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119678010/en/

(L–R) Amit Jain, CEO of Luma AI, and Tareq Amin, CEO of HUMAIN, at the U.S.–Saudi Investment Forum in Washington, D.C., where Luma AI announced its $900 million Series C and partnership on Project Halo - a 2-gigawatt AI supercluster in Saudi Arabia that will power next-generation World Models and accelerate the path toward Multimodal AGI.
This Series C is a milestone in the company’s mission to build multimodal general intelligence: AI that can generate, understand, and operate in the physical world. To train and deploy these next-generation AI systems, Luma AI will become a customer of HUMAIN as HUMAIN builds Project Halo, a 2-gigawatt AI supercluster in Saudi Arabia, making it one of the world’s largest compute infrastructure buildouts.
Announced today in Washington, D.C., at the U.S.- Saudi Investment Forum on the visit of the Crown Prince HRH Mohammad bin Salman Al-Saud, the companies unveiled a joint roadmap to advance the frontier of multimodal intelligence. This new funding and infrastructure will accelerate Luma AI's efforts to train large-scale World Models, foundational AI that goes beyond LLMs and learns from humanity’s digital footprint in video, audio, and language, to build products in HUMAIN Create that understand and simulate reality for robotics, entertainment, advertising, gaming, and personalized education at a global scale.
“HUMAIN is the perfect partner for this next stage in Luma AI’s explosive trajectory,” said Amit Jain, CEO and co-founder of Luma AI. “To create AI that can help humanity in the physical world and expand our understanding of the universe, we need to build systems that can learn from a quadrillion tokens of information - roughly the collective digital memory of humanity - contained in video, image, audio, and language. HUMAIN is deploying frontier compute infrastructure at impressive speed, and this is critical to achieving Luma AI’s mission. We are also partnering deeply across customized models, go-to-market, and deployment of frontier capabilities to build a full end-to-end value-chain for multimodal AI.”
“This investment underscores an important point in HUMAIN’s philosophy: we are not only funding the next wave of AI, we’re building the full value chain that makes it possible,” said Tareq Amin, CEO of HUMAIN. “Luma AI is an exceptional U.S.-based global frontier startup pushing the boundaries of multimodal world models. Their technical ambition, research velocity, and proven ability to turn foundational breakthroughs into real products make them uniquely aligned with HUMAIN’s vision. Our investment in Luma AI, combined with HUMAIN’s 2GW supercluster, positions us to train, deploy, and scale multimodal intelligence at a frontier level. This partnership sets a new benchmark for how capital, compute, and capability come together."
The new 2-gigawatt supercluster represents a giant leap for multimodal AI infrastructure. Luma is developing technology capable of efficiently training on peta-scale multimodal data – 1,000-10,000 times more information than the current frontier Large Language Models (LLMs) to make AI useful for real-world tasks. This cluster will also feature next-generation inference systems engineered to serve these models globally in real-time. “It is only through this level of systems and algorithmic integration that it is possible to build models that can understand and simulate the universe,” added Jain.
Ray3, Luma AI’s flagship model, has already demonstrated Luma AI’s ability to transform foundational research into scalable commercial products, deployed widely in studios, ad agencies, and brands, including being embedded within Adobe’s global products and solutions. With this new round of funding, Luma AI plans to extend its leadership in entertainment and advertising into simulation, design, and robotics.
As previously reported, Luma AI was the first set of models to be launched within HUMAIN Create, a regional initiative focused on building sovereign AI models and end-to-end products designed for the Arabic world. These models will understand cultural context, visual nuance, and linguistic diversity, empowering creators, enterprises, and governments to adopt AI that reflects their identity, values, and sovereignty.
About Luma AI
Luma AI is building a multimodal general intelligence that can generate, understand, and operate in the physical world. Its flagship platform, Dream Machine, enables creatives everywhere to generate professional-grade video and images. In 2025, Luma released Ray3, the world’s first reasoning video model capable of creating physically accurate videos, animations, and visuals. Luma’s models are utilized by top entertainment studios, ad agencies, and technology leaders, including Adobe and AWS, and are available via subscription or API. The company is backed by HUMAIN, Andreessen Horowitz, Amazon, AMD Ventures, NVIDIA, Amplify Partners, Matrix Partners, and angels from across the technology and entertainment space.
About HUMAIN
HUMAIN, a PIF company, is a global artificial intelligence company delivering full-stack AI capabilities across four core areas: next-generation data centers, hyper-performance infrastructure & cloud platforms, advanced AI Models, including the world’s most advanced Arabic LLMs built in the Arab world, and transformative AI Solutions that combine deep sector insight with real-world execution.
HUMAIN’s end-to-end model serves both public and private sector organizations, unlocking exponential value across all industries, driving transformation and strengthening capabilities through human-AI synergies. With a growing portfolio of sector-specific AI products and a core mission to drive IP leadership and talent supremacy world-wide, HUMAIN is engineered for global competitiveness and national distinction.
Forward-Looking Statement
This press release contains forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to uncertainties. HUMAIN undertakes no obligation to update these statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251119678010/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom